Featured Research

from universities, journals, and other organizations

Two new possible drug targets for triple negative breast cancer

Date:
May 27, 2014
Source:
Houston Methodist
Summary:
The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists. The findings may help medical researchers identify effective drug targets for triple negative breast cancer, or TNBC. About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses.

The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings of the National Academy of Sciences (now online). The findings may help medical researchers identify effective drug targets for triple negative breast cancer, or TNBC.

Related Articles


The genes, MLF2 (myeloid leukemia factor 2) and RPL39 (a ribosomal protein), were found to most profoundly impact the production of nitric oxide synthase, which helps regulate blood vessel behavior and could be crucial to the recruitment of new blood vessels to growing tumors. These genes impact the spread of TNBC throughout the body, and have not so far been linked with breast cancer.

"We have found two unique genes that may affect the most lethal type of breast cancer" said principal investigator and Houston Methodist Cancer Center Director Jenny Chang, M.D., "Most importantly, by knowing how these genes function, we have drugs that can block nitric oxide signaling and will begin a clinical trial in the Cancer Center in the near future"

About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses. Patients typically relapse within one to three years of being treated. TNBC is distinguished from other breast cancers in that it does not express the genes for estrogen receptor, progesterone receptor, and Her2/neu and is frequently harder to treat.

By suppressing close to five hundred TNBC-related genes, Chang's group found interference was strongest with MLF2 and RPL39 in triple negative breast cancer model tissue. The scientists also learned that mutations in these genes in human patients were associated with worse survival in (human) triple negative breast cancer patients.

The researchers went a step further, determining which configurations of small inhibitory RNA (siRNA) were most efficient at shutting down MLF2 and RPL39 in breast cancer stem cell lines. siRNA molecules interfere with the cell's ability to express genes and have proven to be effective drug tools for a wide variety of diseases, including some cancers.

In preliminary studies, the combination of siRNA and chemotherapy agent docetaxel significantly reduced tumor volume relative to chemotherapy alone and also appeared to prolong survival. Separate analyses showed suppression with siRNA appeared to yield fewer metastases to lung tissue.

Earlier this year, Chang, Weill Cornell Medical College Dean Laurie Glimcher, M.D., and colleagues reported to Nature another possible drug target for TNBC patients called XBP1, another gene previously unassociated with breast cancer.

"Together with our colleagues in Weill Cornell, we are launching clinical trials that affect these unique novel pathways that may cause TNBC to spread. These trials have potential to significantly impact this highly aggressive form of breast cancer."


Story Source:

The above story is based on materials provided by Houston Methodist. Note: Materials may be edited for content and length.


Journal Reference:

  1. B. Dave, S. Granados-Principal, R. Zhu, S. Benz, S. Rabizadeh, P. Soon-Shiong, K.-D. Yu, Z. Shao, X. Li, M. Gilcrease, Z. Lai, Y. Chen, T. H.- M. Huang, H. Shen, X. Liu, M. Ferrari, M. Zhan, S. T. C. Wong, M. Kumaraswami, V. Mittal, X. Chen, S. S. Gross, J. C. Chang. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences, 2014; DOI: 10.1073/pnas.1320769111

Cite This Page:

Houston Methodist. "Two new possible drug targets for triple negative breast cancer." ScienceDaily. ScienceDaily, 27 May 2014. <www.sciencedaily.com/releases/2014/05/140527114304.htm>.
Houston Methodist. (2014, May 27). Two new possible drug targets for triple negative breast cancer. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2014/05/140527114304.htm
Houston Methodist. "Two new possible drug targets for triple negative breast cancer." ScienceDaily. www.sciencedaily.com/releases/2014/05/140527114304.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins